Markus Manns
Markus Manns is a portfolio manager at Union Investment, where he focuses on healthcare investments. He has commented on BioNTech's strategic developments in the oncology field, particularly regarding the promising bispecific antibody BNT327, which combines mechanisms to enhance cancer treatment efficacy. Manns has praised the collaboration between BioNTech and Bristol Myers Squibb as a significant move in cancer research.
Not in the pool (under ¢1).
Recent news mentions
Markus Manns from Union Investment stated that the decision is an important milestone for Bayer in reducing glyphosate risks.
Trump-Regierung unterstützt Bayer im Glyphosat-Streit - Wirtschaft
Germany· 2025-12-02
Markus Manns described the results as the 'best possible scenario for Novo'.
Na trg vstopa tableta za hujšanje, ki naj bi postala vodilna na trgu
Slovenia· 2025-08-25
Markus Manns described the cuts to Novo's growth outlook as 'a shocker'.
Wegovy maker Novo Nordisk warns of slower profits as rivals bite
United Kingdom· 2025-07-29
Markus Manns is a portfolio manager at Union Investment who commented on the promising developments in cancer medicine.
Wie BioNTech die Krebsmedizin aufmischen will
Switzerland· 2025-06-19
